HLB BioStep Co (XKRX:278650) Net Income (Continuing Operations): ₩-20,457 Mil (TTM As of Mar. 2026)


XKRX:278650 HLB BioStep Co Ltd XKRX:278650
67 GF Score
Price ₩2,820.00
GF Value ₩7,609.68
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is HLB BioStep Co Net Income (Continuing Operations)?

HLB BioStep Co XKRX:278650 -6.31% 67 Net Income (Continuing Operations) is ₩-20,457 Mil as of Mar. 2026. GuruFocus rates XKRX:278650 with a GF Score™ of 67/100 and a GF Value™ of ₩7,609.68 (Possible Value Trap). The stock has 2 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. HLB BioStep Co's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was ₩-2,116 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was ₩-20,457 Mil.

HLB BioStep Co  (XKRX:278650) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

HLB BioStep Co Net Income (Continuing Operations) Related Terms

HLB BioStep Co Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for HLB BioStep Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLB BioStep Co Net Income (Continuing Operations) Chart

HLB BioStep Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,531.95 -882.73 -54.24 -9,692.63 -20,255.13

HLB BioStep Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,834.79 -4,569.80 770.18 -14,541.19 -2,115.94
XKRX:278650
67GF Score
HLB BioStep Co Ltd XKRX:278650
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLB BioStep Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-20,457 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of ₩-20,457 Mil mean?
HLB BioStep Co (XKRX:278650) has a Net Income (Continuing Operations) of ₩-20,457 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on HLB BioStep Co and its competitors.
Is HLB BioStep Co's Net Income (Continuing Operations) too high?
HLB BioStep Co's current Net Income (Continuing Operations) is ₩-20,457 Mil. Overall, HLB BioStep Co has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HLB BioStep Co's Net Income (Continuing Operations) compare to VRTX and REGN?
HLB BioStep Co's Net Income (Continuing Operations) of ₩-20,457 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on HLB BioStep Co and its competitors. HLB BioStep Co's current Net Income (Continuing Operations) is ₩-20,457 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLB BioStep Co stock overvalued right now?
Based on GuruFocus' analysis, HLB BioStep Co (XKRX:278650) is currently considered Possible Value Trap. The stock's GF Value™ is ₩7,609.68, compared to a current price of ₩2,820.00 — trading 62.9% below its estimated fair value. The current Net Income (Continuing Operations) is ₩-20,457 Mil. HLB BioStep Co's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For HLB BioStep Co (XKRX:278650), the current Net Income (Continuing Operations) is ₩-20,457 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLB BioStep Co (XKRX:278650) Overvalued in 2026?

Based on GuruFocus' analysis, HLB BioStep Co stock appears to be undervalued. The current stock price of ₩2,820.00 is trading 62.9% below its estimated GF Value™ of ₩7,609.68. GuruFocus considers HLB BioStep Co to be Possible Value Trap.

Key valuation signals for XKRX:278650:

  • Net Income (Continuing Operations): ₩-20,457 Mil
  • GF Value™: ₩7,609.68 vs. price of ₩2,820.00 (62.9% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the XKRX:278650 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLB BioStep Co Business Description

Address 38, Academy-ro 79beon-gil, Yeonsu-gu, Incheon, KOR, 22014
HLB BioStep Co Ltd provides non-clinical services necessary for leading domestic and foreign pharmaceutical companies and bio ventures in the process of developing drugs and health functional foods.
67GF Score

Get the complete analysis for XKRX:278650

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩2,820.00
Price
₩7,609.68
GF Value